Indivior Reports Pretax Profit Jump, Considers U.S. Listing

Indivior Considers Moving Primary Listing to the U.S. as it Reports Fourth-Quarter Profit

Pharmaceutical company, Indivior, announced on Thursday that it is considering moving its primary listing from the U.K. to the U.S. by 2024, as it reported a fourth-quarter pretax profit. The potential move comes as Indivior aims to align its listing with its focus on the U.S., where its proprietary products are centered.